All Phenotypes Nrbp1<tm1.1Dja> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Nrbp1^tm1.1Dja/Nrbp1^tm1.2Dja Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J	MGI:5427573
cn2	Nrbp1^tm1.1Dja/Nrbp1^tm1.2Dja Lgr5^{tm1(cre/ERT2)Cle}/Lgr5⁺	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J	MGI:5427571
cn3	Nrbp1^tm1.1Dja/Nrbp1^tm1.1Dja Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J	MGI:5427574

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

respiratory system

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

mortality/aging

decreased tumor-free survival time ( J:184685 )

• moribund as early as 3 days post tamoxifen treatment

• 75% of mice die 9 days after tamoxifen treatment

• mice treated with a low dose of tamoxifen exhibit increased death associated with tumorigenesis

digestive/alimentary system

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

abnormal intestine morphology ( J:184685 )

• loss of architecture in tamoxifen-treated mice with reduction in numbers of differentiated cells, cells showing dysplastic nuclear atypia, widespread crypt elongation, increased crypt fission and reduction in villous length

abnormal intestinal mucosa morphology ( J:184685 )

• in tamoxifen-treated mice

abnormal intestinal goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal intestinal enteroendocrine cell morphology ( J:184685 )

• reduced numbers in tamoxifen-treated mice

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

distended stomach ( J:184685 )

• in tamoxifen-treated mice

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

neoplasm

increased tumor incidence ( J:184685 )

• tamoxifen-treated mice exhibit increased incidence of tumorigenesis, including lymphomas/leukemias and solid tumors (angiosarcoma, gastrointestinal adenoma, gastrointestinal adenocarcinoma and lung carcinoma)

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

increased leukemia incidence ( J:184685 )

• in tamoxifen-treated mice

increased lymphoma incidence ( J:184685 )

• in tamoxifen-treated mice

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

liver/biliary system

abnormal liver morphology ( J:184685 )

• tamoxifen-treated mice exhibit zone 3 hydropic changes indicative of malnutrition unlike control mice

homeostasis/metabolism

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

cellular

abnormal intestinal goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

Allelic Composition	Nrbp1^tm1.1Dja/Nrbp1^tm1.2Dja Lgr5^{tm1(cre/ERT2)Cle}/Lgr5⁺
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lgr5^{tm1(cre/ERT2)Cle} mutation (1 available); any Lgr5 mutation (58 available)
Nrbp1^tm1.1Dja mutation (0 available); any Nrbp1 mutation (52 available)
Nrbp1^tm1.2Dja mutation (0 available); any Nrbp1 mutation (52 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

digestive/alimentary system

abnormal intestine morphology ( J:184685 )

• authors state that tamoxifen-treated mice exhibit similar phenotype as Nrbp1^tm1.1Dja/Nrbp1^tm1.1Dja Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/ Gt(ROSA)26Sor⁺ mice

abnormal intestinal goblet cell morphology ( J:184685 )

• abnormal goblet cell production in tamoxifen-treated mice

abnormal Paneth cell morphology ( J:184685 )

• abnormal granularization of Paneth cells in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• abnormal localization of Paneth cells in tamoxifen-treated mice

endocrine/exocrine glands

abnormal Paneth cell morphology ( J:184685 )

• abnormal granularization of Paneth cells in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• abnormal localization of Paneth cells in tamoxifen-treated mice

cellular

abnormal intestinal goblet cell morphology ( J:184685 )

• abnormal goblet cell production in tamoxifen-treated mice

Allelic Composition	Nrbp1^tm1.1Dja/Nrbp1^tm1.1Dja Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (992 available)
Nrbp1^tm1.1Dja mutation (0 available); any Nrbp1 mutation (52 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

decreased tumor-free survival time ( J:184685 )

• moribund as early as 3 days post tamoxifen treatment

• 75% of mice die 9 days after tamoxifen treatment

• mice treated with a low dose of tamoxifen exhibit increased death associated with tumorigenesis

respiratory system

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

digestive/alimentary system

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

abnormal intestine morphology ( J:184685 )

abnormal intestinal mucosa morphology ( J:184685 )

• in tamoxifen-treated mice

abnormal intestinal goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal intestinal enteroendocrine cell morphology ( J:184685 )

• reduced numbers in tamoxifen-treated mice

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

distended stomach ( J:184685 )

• in tamoxifen-treated mice

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

neoplasm

increased tumor incidence ( J:184685 )

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

increased leukemia incidence ( J:184685 )

• in tamoxifen-treated mice

increased lymphoma incidence ( J:184685 )

• in tamoxifen-treated mice

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

liver/biliary system

abnormal liver morphology ( J:184685 )

• tamoxifen-treated mice exhibit zone 3 hydropic changes indicative of malnutrition unlike control mice

homeostasis/metabolism

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

cellular

abnormal intestinal goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 10/29/2024 MGI 6.24